Core Insights - Viking Therapeutics announced new clinical data from the VK2735 obesity program, showing improvements in cardiometabolic parameters after 13 weeks of treatment, including reductions in prediabetes and metabolic syndrome prevalence [1][5]. Clinical Trial Results - In the Phase 2 VENTURE clinical trial, 78% of VK2735-treated patients who were prediabetic at baseline achieved normal glycemic status by Week 13, compared to 29% in the placebo group (p=0.0008) [2]. - Among patients with metabolic syndrome at baseline, 68% of those treated with VK2735 no longer met the criteria for the syndrome at Week 13, versus 38% for placebo (p=0.02) [3]. Weight Loss and Safety - VK2735 treatment resulted in statistically significant mean body weight reductions of up to 14.7% from baseline after 13 weeks, with 88% of VK2735 patients achieving at least 10% weight loss compared to 4% for placebo [6]. - The treatment demonstrated a favorable safety profile, with 92% of treatment-emergent adverse events classified as mild or moderate [7]. Future Studies - Viking is conducting a Phase 3 study (VANQUISH-1) to evaluate VK2735's effects on body weight and other health parameters in patients with obesity or overweight and related comorbidities [5][9].